News coverage about Compugen (NASDAQ:CGEN) has been trending somewhat positive on Wednesday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Compugen earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.7443081547163 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several research analysts have issued reports on the company. Zacks Investment Research lowered Compugen from a “hold” rating to a “sell” rating in a report on Friday, August 4th. FBR & Co set a $14.00 price target on Compugen and gave the stock a “buy” rating in a report on Friday, May 19th.
Compugen (NASDAQ:CGEN) opened at 3.35 on Wednesday. The company’s market cap is $171.29 million. Compugen has a one year low of $2.60 and a one year high of $6.93. The firm has a 50-day moving average price of $3.32 and a 200 day moving average price of $3.94.
Compugen (NASDAQ:CGEN) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Compugen had a negative return on equity of 57.69% and a negative net margin of 4,425.00%. Equities analysts expect that Compugen will post ($0.73) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/09/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-compugen-cgen-stock-price.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.